Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262846 · ClinicalTrials.gov registry record · Phase 4
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
A Phase 4 study of HIV Infection, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT01262846: Completed Phase 4 study of HIV Infection, sponsored by University of Pennsylvania.
NCT01262846 is a Phase 4 study of HIV Infection that has completed, run by University of Pennsylvania. The registered enrollment target is 195 participants, below the 240-participant average among 73 other HIV Infection trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01262846, a Phase 4 study of HIV Infection, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals. Our hypothesis is that Fluzone® HD will be safe and more immunogenic than the currently used vaccine
Primary Outcome
To compare the immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone®
Study Locations (1)
Pennsylvania
- Clinical Trials Unit. University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
What the finished NCT01262846 record still lists
NCT01262846 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 240-participant average among 73 other HIV Infection trials with a reported enrollment target (19% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Fluzone® is the first listed.
NCT01262846 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01262846 about?
NCT01262846 is a clinical study titled "Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals". The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals. Our hypothesis is that Fluzone® HD will be safe and more immunogenic than the currently used vaccine
What is the current status of trial NCT01262846?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 195 participants. The study started on 2010-11. Estimated completion is 2011-04.
What conditions does trial NCT01262846 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT01262846?
The interventions under investigation include: Fluzone® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01262846?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01262846 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01262846's enrollment target sits among peer trials
195 19th of 73 higher than 55 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
Safety and Efficacy Study of Switching From Epzicom to Truvada
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia